longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Bausch Health

BHC

6.1604.20% ( -0.270 )
Closed: Sep 9, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -2.10, below the reasonable range, cheaper than 89.31% of the time in the past 1 years, and the industry ranks 129/258, the industry Median -1.41.

-2.1xP/E
$6.16Stock price
$-2.94Earnings per share
-2.1xP/E
Stock price$6.16Earnings per share$-2.94

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
6.81x
Typical range
-1.64x–13.50x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-55.10x14.01%$57.53B
BAYZFUSBayer Aktiengesellschaft
-27.51x--$55.50B
BAYRYUSBayer
-27.87x--$56.23B
VTRSUSViatris
-46.14x107.02%$18.95B
ELANUSElanco Animal Health
-59.13x129.36%$11.77B
VREOFUSVIREO GROWTH INC
-171.96x--$11.54B
AXSMUSAxsome Therap
-57.57x27.32%$11.03B
CURLFUSCuraleaf Holdings, Inc.
-150.07x--$7.81B
BLTEUSBelite Bio
-72.06x29.87%$7.38B
DFTXUSDefinium Therapeutics
-14.43x53.67%$5.10B
EWTXUSEdgewise Therapeutics
-23.89x137.29%$4.71B
ELVNUSEnliven Therapeutics
-39.74x1.17%$4.21B
MANEUSVeraDermics
-39.93x97.39%$4.16B
AMLXUSAmylyx Pharmaceuticals
-26.74x1.76%$4.07B
TARSUSTarsus Pharmaceuticals
-78.15x34.09%$3.63B
MBXUSMBX Biosciences
-29.05x32.19%$3.03B
GPCRUSStructure Therapeutics
-13.68x104.48%$2.94B
RGCUSRegencell Bioscience
-411.22x--$2.90B
ATAIUSAtaiBeckley
-4.05x86.14%$2.70B
PHVSUSPharvaris BV
-13.35x7.47%$2.65B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.